Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates
Intellia Therapeutics Names Bill Chase to its Board of Directors
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics Announces Proposed Public Offering of Common Stock